Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Pralatrexate Solution for Intravenous Injection Articles

Spectrum extends tender offer for Allos

9 July 2012

Spectrum plunges on negative trial results; makes bid for Allos

10 April 2012

Allos Thera questions CHMP Folotyn decision; posts new data

31 January 2012

Allos Therapeutics and Mundipharma ink $360 million deal for Folotyn

13 May 2011

Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million

3 February 2010

Celgene buys rival Gloucester for $640 million, gaining rights to Istodax; Allos defends price of Folotyn

8 December 2009

US FDA approves J&J’s psoriasis drug Stelara and Allos’ cancer agent Folotyn

28 September 2009

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS